This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Share
Stay up to date

Home
Topics
Webinars/Videos
Infographics
Articles
Case Studies
Forum
Faculty
Unblocked
Stay up to date

Articles

Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial

Sayah N, Bhatt DL, Miller M, et al.

Journal:

Eur Heart J

First published: January 22, 2024 DOI: 10.1093/eurheartj/ehad889

Abstract

You might also like...

Running time: 19 minutes
Webinars/Videos
The Year in Lipids- AHA Highlights in ASCVD and Lipids
Listen to Prof. Lale Tokgözoğlu summarizing the year in Lipids and discussing the highlights from this year’s AHA Scientific Sessions.
Sayah N, Bhatt DL, Miller M, et al.
Journal:
Eur Heart J

First published: January 22, 2024 DOI: 10.1093/eurheartj/ehad889
View
- Share
Infographics
Clinical benefits of icosapent ethyl in cardiovascular disease: findings from REDUCE-IT trials
Check out and download our latest infographics highlighting the important findings of the REDUCE-IT Trials. The multicenter, placebo-controlled, double-blind trial REDUCE-IT assesses the therapeutic effects of icosapent ethyl, a stable eicosapentaenoic acid ethyl ester, in such patients.
Sayah N, Bhatt DL, Miller M, et al.
Journal:
Eur Heart J

First published: January 22, 2024 DOI: 10.1093/eurheartj/ehad889
View
- Share
Case Studies
Quiz of the month – September 2021
What is your preferred reference format to support clinical decision-making?
Sayah N, Bhatt DL, Miller M, et al.
Journal:
Eur Heart J

First published: January 22, 2024 DOI: 10.1093/eurheartj/ehad889
Take
- Share

How would you rate this content?

© John Wiley & Sons, Ltd. All rights reserved.
Privacy Policy
Terms of use
Stay up to date
Cookie Preferences
This Knowledge Hub is supported by Novartis.